WO2014143807A3 - Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders - Google Patents

Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders Download PDF

Info

Publication number
WO2014143807A3
WO2014143807A3 PCT/US2014/027935 US2014027935W WO2014143807A3 WO 2014143807 A3 WO2014143807 A3 WO 2014143807A3 US 2014027935 W US2014027935 W US 2014027935W WO 2014143807 A3 WO2014143807 A3 WO 2014143807A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
pathway antagonist
bcr pathway
disorders
treatment
Prior art date
Application number
PCT/US2014/027935
Other languages
French (fr)
Other versions
WO2014143807A2 (en
Inventor
Scott STROMATT
Original Assignee
Stromatt Scott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stromatt Scott filed Critical Stromatt Scott
Publication of WO2014143807A2 publication Critical patent/WO2014143807A2/en
Publication of WO2014143807A3 publication Critical patent/WO2014143807A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods of treating a patient with a B-cell malignancy or disorder comprising administering an anti-CD37 antibody or antibody fragment in combination with a BCR pathway antagonist such as a SYK inhibitor, a BTK inhibitor or a CXCR4 antagonist. In one embodiment, the invention provides methods for B-cell reduction comprising contacting B-cells with an anti-CD37 antibody or antibody fragment and a BCR pathway antagonist. The invention includes compositions and kits comprising anti-CD37 antibody and antibody fragments for use in combination with a BCR pathway antagonist.
PCT/US2014/027935 2013-03-15 2014-03-14 Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders WO2014143807A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361801494P 2013-03-15 2013-03-15
US61/801,494 2013-03-15
US201361820540P 2013-05-07 2013-05-07
US61/820,540 2013-05-07
US201361913144P 2013-12-06 2013-12-06
US61/913,144 2013-12-06

Publications (2)

Publication Number Publication Date
WO2014143807A2 WO2014143807A2 (en) 2014-09-18
WO2014143807A3 true WO2014143807A3 (en) 2014-12-18

Family

ID=51538275

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/027935 WO2014143807A2 (en) 2013-03-15 2014-03-14 Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders

Country Status (1)

Country Link
WO (1) WO2014143807A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102971012B (en) 2010-03-12 2016-05-04 伊缪诺金公司 CD37 binding molecule and immunoconjugates thereof
CN103596590A (en) 2011-04-01 2014-02-19 伊缪诺金公司 Cd37-binding molecules and immune conjugates thereof
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
HRP20212021T1 (en) 2011-07-19 2022-04-01 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
AU2014358868A1 (en) 2013-12-05 2016-06-09 Acerta Pharma B.V. Therapeutic combination of a PI3K inhibitor and a BTK inhibitor
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
CN105017256A (en) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 Polyfluorinated compound Bruton tyrosine kinase inhibitor
US9949971B2 (en) 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
DK3179991T3 (en) 2014-08-11 2021-12-06 Acerta Pharma Bv THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR AND A BCL-2 INHIBITOR
WO2016090255A1 (en) * 2014-12-05 2016-06-09 Sriram Balasubramanian Biological markers for predicting responsiveness to ibrutinib and r-chop combination therapy and methods of using the same
DK3050574T3 (en) * 2015-01-28 2020-01-20 Univ Bordeaux Use of plerixafor for the treatment and / or prevention of acute exacerbations of chronic obstructive pulmonary disease
US10392425B2 (en) * 2015-02-05 2019-08-27 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising Shiga toxin A subunit effector regions and enriched compositions thereof
CN106146508A (en) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 The drug combination optimized and treatment cancer and the purposes of autoimmune disease thereof
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
JP6823587B2 (en) 2015-04-13 2021-02-03 第一三共株式会社 Combination therapy with MDM2 inhibitor and BTK inhibitor
JP6979877B2 (en) * 2015-06-08 2021-12-15 デビオファーム インターナショナル， エス． アー． Combination of anti-CD37 immunoconjugate and anti-CD20 antibody
LT3613745T (en) 2015-07-02 2021-10-11 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
MX2018002467A (en) 2015-08-28 2018-06-15 Debiopharm Int Sa Antibodies and assays for detection of cd37.
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
US11242400B2 (en) 2016-09-21 2022-02-08 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
EP3535297B1 (en) * 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
TW201922256A (en) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 Methods for treating lymphoid malignancies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LU ET AL.: "Therapeutic advancement of chronic lymphocytic leukemia.", J HEMATOL ONCOL, vol. 5, 16 September 2012 (2012-09-16), pages 12PP *
VLAD ET AL.: "Down-regulation of CXCR4 and CD 62L in chronic lymphocytic leukemia cells is triggered by B- cell receptor ligation and associated with progressive disease.", CANCER RES, vol. 69, no. 16, 15 August 2009 (2009-08-15), pages 6387 - 6395 *

Also Published As

Publication number Publication date
WO2014143807A2 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
WO2014143807A3 (en) Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
WO2015116729A3 (en) Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
MA39906A (en) Combination therapies for the treatment of cancer
MX2016015181A (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer.
MX2021008113A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
HK1213925A1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer 18.2
MX2015002947A (en) Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor.
MX2016013218A (en) Trifunctional antigen-binding molecule.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2016004736A (en) Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody.
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2016002645A (en) Combination therapy for the treatment of glioblastoma.
EA201490194A1 (en) COMBINED THERAPY, INCLUDING CDK4 / 6 INHIBITOR AND PI3K INHIBITOR FOR USE IN CANCER TREATMENT
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
MX370417B (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases.
BR112017023517A2 (en) anti-cd20 antibody for cancer treatment, pharmaceutical composition, method of treating a cancer patient and use of an anti-cd20 antibody
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2019001977A (en) Methods and compositions for treating multiple sclerosis and related disorders.
IL247586A0 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
RS63738B1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MX2021011799A (en) Semaphorin-4d antagonists for use in cancer therapy.
HK1258235A1 (en) Inhibitors of pi3k p-delta 110 for use in delivery of viruses in the treatment of cancer
MX2016010948A (en) Compositions and methods for identifying b cell malignancies responsive to b cell depleting therapy.
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14762629

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14762629

Country of ref document: EP

Kind code of ref document: A2